{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T04:39:19Z","timestamp":1792471159464,"version":"4.5.0"},"reference-count":44,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"20","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,20]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Chronic hepatitis B virus (HBV) infection accounts for more than 40% of hepatocellular carcinoma (HCC) cases worldwide. The GALAD (Gender, Age, alpha fetoprotein heterogeneity [AFP-L3], AFP, and des-gamma-carboxy prothrombin [DCP]) model has potential for enhancing HCC diagnosis. However, its diagnostic performance in HBV-associated chronic liver disease requires further optimization. This study aimed to establish a diagnostic model for HBV-associated HCC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>The data from 2190 patients with HBV-related liver diseases, including chronic hepatitis B (CHB), cirrhosis, and HCC were analysed. The GADA model was developed by omitting AFP-L3 for improved accessibility, and its performance was assessed via the area under the receiver operating characteristic curve (AUC). Validation was performed on 20,908 patients across ten hospitals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The simplified GADA model demonstrated exceptional diagnostic performance in identifying HBV-related HCC in the modeling group, achieving an AUC of 0.940 (95% CI, 0.927\u20130.952), with a sensitivity and specificity of 82.57% and 91.53%, respectively, surpassing the original GALAD model\u2019s AUC of 0.907 (95% CI, 0.891\u20130.921). In the internal validation cohort, the GADA model had an AUC of 0.935 (95% CI, 0.914\u20130.953), sensitivity of 82.04%, and specificity of 92.65%. For early-stage HCC detection, the AUC in the modeling group was 0.858 (95% CI, 0.837\u20130.877), and in the internal validation group was 0.868 (95% CI, 0.836\u20130.895), significantly better than the original GALAD model. External validation with 20,908 participants yielded an AUC of 0.919 (95% CI, 0.916\u20130.923), with sensitivity of 86.00% and specificity 81.88%. For early-stage HCC diagnosis, the AUC was 0.903 (95% CI: 0.898\u20130.907), with sensitivity of 88.16% and specificity 74.50%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The GADA model shows exceptional promise for diagnosing HBV-related HCC, enhancing early detection and reducing misdiagnosis rates. Its clinical utility is supported by robust validation, indicating significant implications for patient prognosis and treatment options.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cm9.0000000000004244","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:00:10Z","timestamp":1787025610000},"page":"3110-3119","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Development and validation of GADA model for diagnosing hepatocellular carcinoma in Chinese hepatitis B patients"],"prefix":"10.1097","volume":"139","author":[{"given":"Mingjie","family":"Yao","sequence":"first","affiliation":[{"name":"Department of Anatomy and Embryology, School of Basic Medical Sciences, Peking University Health Science Center, Beijing 100191, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamei","family":"Wei","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, School of Medicine, Shihezi University, Shihezi, Xinjiang 832003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weilin","family":"Gu","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Infectious Disease Center, School of Basic Medicine, Peking University Health Science Center, Beijing 100191, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Infectious Disease Center, School of Basic Medicine, Peking University Health Science Center, Beijing 100191, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zian","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Laboratory, Qinghai Provincial People\u2019s Hospital, Xining, Qinghai 810000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dazhi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, Shenzhen Third People\u2019s Hospital, Southern University of Science and Technology, National Clinical Research Center for Infectious Diseases, Shenzhen, Guangdong 518112, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingxian","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Hepatopathy, The Third People\u2019s Hospital of Shenzhen, the Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong 518112, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Hepatopathy, The Third People\u2019s Hospital of Shenzhen, the Second Affiliated Hospital of Southern University of Science and Technology, Shenzhen, Guangdong 518112, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Xia","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoxin","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Peking University Shenzhen Hospital, Shenzhen, Guangdong 518036, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Lou","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China; Key Laboratory of Clinical In Vitro Diagnostic Techniques of Zhejiang Province, Hangzhou, Zhejiang 310003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Union Hospital, Wuhan University, Wuhan, Hubei 430000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Can","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian 350005, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongsong","family":"Chen","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Hepatology Institute, Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Diseases, Beijing International Cooperation Base for Science and Technology on NAFLD Diagnosis, Infectious Disease and Hepatology Center of Peking University People\u2019s Hospital, Beijing 100044, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunping","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory, the Second Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dexiang","family":"Zhuo","sequence":"additional","affiliation":[{"name":"The First Hospital of Sanming Affiliated to Fujian Medical University, Sanming, Fujian, 365000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, School of Medicine, Shihezi University, Shihezi, Xinjiang 832003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, School of Medicine, Shihezi University, Shihezi, Xinjiang 832003, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou, Fujian 350025, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengmin","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Microbiology and Infectious Disease Center, School of Basic Medicine, Peking University Health Science Center, Beijing 100191, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"R1-20261020","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1159\/000508568","article-title":"The burden and trends of primary liver cancer caused by specific etiologies from 1990 to 2017 at the global, regional, national, age, and sex level results from the Global Burden of Disease Study 2017","volume":"9","author":"Lin","year":"2020","journal-title":"Liver Cancer"},{"key":"R2-20261020","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2011.12.061","article-title":"Epidemiology of viral hepatitis and hepatocellular carcinoma","volume":"142","author":"El-Serag","year":"2012","journal-title":"Gastroenterology"},{"key":"R3-20261020","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: Management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"R4-20261020","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1007\/s00261-018-1744-4","article-title":"White paper of the Society of Abdominal Radiology hepatocellular carcinoma diagnosis disease-focused panel on LI-RADS v2018 for CT and MRI","volume":"43","author":"Elsayes","year":"2018","journal-title":"Abdom Radiol (NY)"},{"key":"R5-20261020","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijid.2017.09.003","article-title":"Contribution of hepatitis B virus and hepatitis C virus to liver cancer in China north areas: Experience of the Chinese National Cancer Center","volume":"65","author":"Wang","year":"2017","journal-title":"Int J Infect Dis"},{"key":"R6-20261020","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1097\/CM9.0000000000003171","article-title":"Survey of hepatitis B virus infection for liver cancer screening in China: A population-based, cross-sectional study","volume":"137","author":"Xu","year":"2024","journal-title":"Chin Med J"},{"key":"R7-20261020","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.jhep.2024.08.028","article-title":"EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma","volume":"82","year":"2025","journal-title":"J Hepatol"},{"key":"R8-20261020","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/j.gastro.2009.04.005","article-title":"Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma","volume":"137","author":"Marrero","year":"2009","journal-title":"Gastroenterology"},{"key":"R9-20261020","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/nrgastro.2010.100","article-title":"Hepatocellular carcinoma: A global view","volume":"7","author":"Yang","year":"2010","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"R10-20261020","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1158\/1055-9965.EPI-13-0870","article-title":"The detection of hepatocellular carcinoma using a prospectively developed and validated model based on serological biomarkers","volume":"23","author":"Johnson","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R11-20261020","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1158\/1055-9965.EPI-18-0281","article-title":"GALAD score for hepatocellular carcinoma detection in comparison with liver ultrasound and proposal of GALADUS score","volume":"28","author":"Yang","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R12-20261020","doi-asserted-by":"crossref","first-page":"676","DOI":"10.3390\/diagnostics13040676","article-title":"Circulating biomarkers for the early diagnosis and management of hepatocellular carcinoma with potential application in resource-limited settings","volume":"13","author":"Pan","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"R13-20261020","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1159\/000488035","article-title":"Guidelines for diagnosis and treatment of primary liver cancer in China (2017 edition)","volume":"7","author":"Zhou","year":"2018","journal-title":"Liver Cancer"},{"key":"R14-20261020","first-page":"10","article-title":"Guidelines on the diagnosis and treatment of primary liver cancer (2011 edition)","volume":"1","author":"Qin","year":"2012","journal-title":"Chin Clin Oncol"},{"key":"R15-20261020","first-page":"888","article-title":"The guideline of prevention and treatment for chronic hepatitis B: a 2015 update","volume":"23","year":"2015","journal-title":"Chinese Journal of Hepatology"},{"key":"R16-20261020","first-page":"2648","article-title":"Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)","volume":"35","year":"2019","journal-title":"J Clin Hepatol"},{"key":"R17-20261020","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1056\/NEJM199603143341104","article-title":"Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis","volume":"334","author":"Mazzaferro","year":"1996","journal-title":"N Engl J Med"},{"key":"R18-20261020","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: A nonparametric approach","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"key":"R19-20261020","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.cgh.2015.12.042","article-title":"Role of the GALAD and BALAD-2 serologic models in diagnosis of hepatocellular carcinoma and prediction of survival in patients","volume":"14","author":"Berhane","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R20-20261020","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.cgh.2019.11.012","article-title":"GALAD score detects early hepatocellular carcinoma in an international cohort of patients with nonalcoholic steatohepatitis","volume":"18","author":"Best","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R21-20261020","doi-asserted-by":"crossref","first-page":"E130","DOI":"10.1111\/hepr.12544","article-title":"Highly sensitive alpha-fetoprotein, lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxyprothrombin for hepatocellular carcinoma detection","volume":"46","author":"Caviglia","year":"2016","journal-title":"Hepatol Res"},{"key":"R22-20261020","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","article-title":"Global burden of liver disease: 2023 update","volume":"79","author":"Devarbhavi","year":"2023","journal-title":"Journal of Hepatology"},{"key":"R23-20261020","first-page":"2025","article-title":"Hepatocellular carcinoma attributable to hepatitis B, hepatitis C and other risk factors at global, regional and national levels: an updated systematic review and meta-analysis","author":"Cao","year":"2026","journal-title":"GUT"},{"key":"R24-20261020","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1111\/liv.12818","article-title":"Global patterns of hepatocellular carcinoma management from diagnosis to death: The BRIDGE study","volume":"35","author":"Park","year":"2015","journal-title":"Liver Int"},{"key":"R25-20261020","doi-asserted-by":"crossref","DOI":"10.3390\/ijerph17093108","article-title":"Patterns of comorbidity in hepatocellular carcinoma: A network perspective","volume":"17","author":"Mu","year":"2020","journal-title":"Int J Environ Res Public Health"},{"key":"R26-20261020","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1056\/NEJM198405313102204","article-title":"Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma","volume":"310","author":"Liebman","year":"1984","journal-title":"N Engl J Med"},{"key":"R27-20261020","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.bpg.2004.10.003","article-title":"Serological markers of liver cancer","volume":"19","author":"Yuen","year":"2005","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"R28-20261020","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0304-3835(00)00539-5","article-title":"The role of des-gamma-carboxy prothrombin levels in hepatocellular carcinoma and liver tissues","volume":"159","author":"Shimada","year":"2000","journal-title":"Cancer Lett"},{"key":"R29-20261020","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.3748\/wjg.v12.i8.1175","article-title":"Serum tumor markers for detection of hepatocellular carcinoma","volume":"12","author":"Zhou","year":"2006","journal-title":"World J Gastroenterol"},{"key":"R30-20261020","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1159\/000327577","article-title":"Management of hepatocellular carcinoma in Japan: Consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version","volume":"29","author":"Kudo","year":"2011","journal-title":"Dig Dis"},{"key":"R31-20261020","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/jvh.13388","article-title":"Reappraisal of the diagnostic value of alpha-fetoprotein for surveillance of HBV-related hepatocellular carcinoma in the era of antiviral therapy","volume":"28","author":"Qian","year":"2021","journal-title":"J Viral Hepat"},{"key":"R32-20261020","first-page":"1315","article-title":"AFP specificity for HCC surveillance is increased by mitigating liver injury among treated chronic hepatitis B patients with elevated AFP","volume":"12","author":"Yuan","year":"2019","journal-title":"Int J Clin Exp Pathol"},{"key":"R33-20261020","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1186\/s12885-017-3609-6","article-title":"Effectiveness of PIVKA-II in the detection of hepatocellular carcinoma based on real-world clinical data","volume":"17","author":"Yu","year":"2017","journal-title":"BMC Cancer"},{"key":"R34-20261020","doi-asserted-by":"crossref","first-page":"3928","DOI":"10.3748\/wjg.v21.i13.3928","article-title":"Diagnostic value of PIVKA-II and alpha-fetoprotein in hepatitis B virus-associated hepatocellular carcinoma","volume":"21","author":"Seo","year":"2015","journal-title":"World J Gastroenterol"},{"key":"R35-20261020","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153227","article-title":"Diagnostic evaluation of des-gamma-carboxy prothrombin versus \u03b1-fetoprotein for hepatitis B virus-related hepatocellular carcinoma in China: A large-scale, multicentre study","volume":"11","author":"Ji","year":"2016","journal-title":"PloS One"},{"key":"R36-20261020","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1002\/hep.30233","article-title":"Longitudinal assessment of three serum biomarkers to detect very early-stage hepatocellular carcinoma","volume":"69","author":"Choi","year":"2019","journal-title":"Hepatology (Baltimore, MD)"},{"key":"R37-20261020","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2147\/OTT.S229835","article-title":"Dynamic changes in serum markers and their utility in the early diagnosis of all stages of hepatitis B-associated hepatocellular carcinoma","volume":"13","author":"Wu","year":"2020","journal-title":"Onco Targets Ther"},{"key":"R38-20261020","doi-asserted-by":"crossref","DOI":"10.1038\/srep39184","article-title":"Efficacy of PIVKA-II in prediction and early detection of hepatocellular carcinoma: A nested case-control study in Chinese patients","volume":"6","author":"Yu","year":"2016","journal-title":"Sci Rep"},{"key":"R39-20261020","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000346080","article-title":"A combination of \u03b1-fetoprotein and des-\u03b3-carboxy prothrombin is superior in detection of hepatocellular carcinoma","volume":"87","author":"Ertle","year":"2013","journal-title":"Digestion"},{"key":"R40-20261020","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1080\/00365521.2018.1459824","article-title":"Performance of protein induced by vitamin K absence or antagonist-II assessed by chemiluminescence enzyme immunoassay for hepatocellular carcinoma detection: A meta-analysis","volume":"53","author":"Caviglia","year":"2018","journal-title":"Scand J Gastroenterol"},{"key":"R41-20261020","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20180044","article-title":"Clinical utility of decarboxylation prothrombin combined with \u03b1-fetoprotein for diagnosing primary hepatocellular carcinoma","volume":"38","author":"Fu","year":"2018","journal-title":"Biosci Rep"},{"key":"R42-20261020","doi-asserted-by":"crossref","first-page":"603","DOI":"10.3233\/CBM-170551","article-title":"Impact of etiology of chronic liver disease on hepatocellular carcinoma biomarkers","volume":"21","author":"Ricco","year":"2018","journal-title":"Cancer Biomark"},{"key":"R43-20261020","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1097\/CM9.0000000000002641","article-title":"Precision diagnosis of hepatocellular carcinoma","volume":"136","author":"Wang","year":"2023","journal-title":"Chin Med J"},{"key":"R44-20261020","doi-asserted-by":"crossref","first-page":"344","DOI":"10.3109\/00365521.2015.1082190","article-title":"Combined use of AFP, PIVKA-II, and AFP-L3 as tumor markers enhances diagnostic accuracy for hepatocellular carcinoma in cirrhotic patients","volume":"51","author":"Lim","year":"2016","journal-title":"Scand J Gastroenterol"}],"container-title":["Chinese Medical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CM9.0000000000004244","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T04:01:50Z","timestamp":1792468910000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/CM9.0000000000004244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":44,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/cm9.0000000000004244","relation":{},"ISSN":["0366-6999","2542-5641"],"issn-type":[{"value":"0366-6999","type":"print"},{"value":"2542-5641","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"assertion":[{"value":"2025-12-25","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}}]}}